WO2025202979 - SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR DERIVATIVES AS CBP AND/OR P300 DEGRADERS
National phase entry is expected:
Publication Number
WO/2025/202979
Publication Date
02.10.2025
International Application No.
PCT/IB2025/053280
International Filing Date
28.03.2025
Title **
[English]
SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR DERIVATIVES AS CBP AND/OR P300 DEGRADERS
[French]
COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS ET LEURS DÉRIVÉS EN TANT QU'AGENTS DE DÉGRADATION DE CBP ET/OU P300
Applicants **
AURIGENE ONCOLOGY LIMITED
Inventors
ABBINENI, Chandrasekhar
SAMAJDAR, Susanta
TALLURI, Krishna Chaitanya
Priority Data
202441025578
28.03.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2946 | |
| EPO | Filing, Examination, Granting | 21344 | |
| Japan | Filing, Examination, Granting | 2916 | |
| South Korea | Filing, Examination, Granting | 3533 | |
| USA | Filing, Examination, Granting | 16340 |
Total:
47,079
Contact Us
Abstract[English]
The present disclosure provides substituted heterocyclic compounds of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, which are therapeutically useful as CBP and/or p300 degraders. These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to CBP and/or p300 degradation. Compounds of the present disclosure are especially useful for treating cancer, autoimmune, inflammatory and neurodegenerative diseases and disorders. The present disclosure also provides processes for preparation of the compounds and pharmaceutical formulations comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.[French]
La présente invention concerne des composés hétérocycliques substitués de formule (I) ou un sel pharmaceutiquement acceptable de ceux-ci ou un stéréoisomère de ceux-ci, qui sont thérapeutiquement utiles en tant qu'agents de dégradation de CBP et/ou p300. Ces composés sont utiles dans le traitement et/ou la prévention de maladies et/ou de troubles sensibles à la dégradation de CBP et/ou p300. Les composés de la présente invention sont particulièrement utiles pour le traitement du cancer, de maladies et de troubles auto-immuns, inflammatoires et neurodégénératifs. La présente invention concerne également des procédés de préparation des composés et des formulations pharmaceutiques comprenant au moins l'un des composés de formule (I) ou un sel pharmaceutiquement acceptable de ceux-ci ou un stéréoisomère de ceux-ci.